A recent pan-cancer study further demonstrated that SEPHS1 expression was broadly associated with tumor immunity and patient prognosis, showing favorable outcomes in low-grade glioma but poorer survival in hepatocellular carcinoma [46]. This evidence concerns the gene SEPHS1 and neoplasm.